Needham & Company Maintains Hold Rating on Omeros (OMER), Reiterates Belief FDA Will Require Additional Trial for narsoplimab
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Hold rating on Omeros Corp. (NASDAQ: OMER)The analyst quotes: "OMER reported 4Q21 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
